[1]
|
Freddie, B., Jacques, F., Isabelle, S., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.
https://doi.org/10.3322/caac.21492
|
[2]
|
Emsal-Pınar-Topdağı, Y. and Yakup, K. (2016) Endometrial and Ovarian Cancer with MR Imaging Importance of Serum HE4 and CA125 Levels in the Extent of Disease at Evaluation. The Eur-asian Journal of Medicine, 48, 192-198.
https://doi.org/10.5152/eurasianjmed.2016.0259
|
[3]
|
李莉. 血小板参数、CA125、HE4与子宫内膜癌病理特征的相关性分析[D]: [硕士学位论文]. 兰州: 兰州大学, 2022.
|
[4]
|
徐慧, 张晶波, 刘建维, 等. 胰岛素抵抗及雌激素促进子宫内膜癌发生发展的机制研究[J]. 徐州医科大学学报, 2020, 40(12): 877-881.
|
[5]
|
Sundar, S., Balega, J., Crosbie, E., et al. (2017) BGCS Uterine Cancer Guidelines: Recommendations for Practice. European Journal of Obstet-rics, Gynecology, and Reproductive Biology, 213, 71-97.
https://doi.org/10.1016/j.ejogrb.2017.04.015
|
[6]
|
Van Hanegem, N., Prins, M.M.C., Bongers, M.Y., et al. (2015) The Accuracy of Endometrial Sampling in Women with Postmenopausal Bleeding: A Systematic Review and Me-ta-Analysis. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 197, 147-155. https://doi.org/10.1016/j.ejogrb.2015.12.008
|
[7]
|
Braun, M.M., Overbeek-wager, E.A. and Grumbo, R.J. (2016) Diagnosis and Management of Endometrial Cancer. American Family Physician, 93, 468-474.
|
[8]
|
Tanko, N.M., Linkov, F., Bapayeva, G., et al. (2021) Pipelle Endometrial Biopsy for Abnormal Uterine Bleeding in Daily Clinical Practice: Why the Approach to Patients Should Be Personalized? Journal of Personalized Medicine, 11, Article No. 970. https://doi.org/10.3390/jpm11100970
|
[9]
|
Bast, R.-C., Klug, T.-L., John, E.-S., et al. (1983) A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer. The New England Journal of Medi-cine, 309, 883-887.
https://doi.org/10.1056/NEJM198310133091503
|
[10]
|
Duk, J.-M., Aalders, J.-G., Fleuren, G.-J., et al. (1986) CA125: A Useful Marker in Endometrial Carcinoma. American Journal of Obstetrics and Gynecology, 155, 1097-1102. https://doi.org/10.1016/0002-9378(86)90358-3
|
[11]
|
Bian, J., Sun, X.X., Li, B., et al. (2016) Clinical Significance of Serum HE4, CA125, CA724, and CA19-9 in Patients with Endometrial Cancer. Technology in Cancer Research & Treatment, 16, 435-439.
https://doi.org/10.1177/1533034616666644
|
[12]
|
范余娟, 邹靖, 徐红, 等. 子宫内膜癌γ-synuclein表达和血清CA_(125)水平及与临床病理特征关系的研究[J]. 实用妇产科杂志, 2012, 28(3): 221-224.
|
[13]
|
Ota, S., Sugiyama, T., Ushijima, K., et al. (2000) Successful Treatment of Two Patients with Recurrent Endometrial Cancer by Weekly Paclitaxel. Cancer Letters, 160, 9-12. https://doi.org/10.1016/S0304-3835(00)00548-6
|
[14]
|
Kirchhoff, C., Habben, I., Ivell, R., et al. (1991) A Major Human Epididymis-Specific cDNA Encodes a Protein with Sequence Homology to Extracellular Proteinase Inhibitors. Biology of Reproduction, 45, 350-357.
https://doi.org/10.1095/biolreprod45.2.350
|
[15]
|
Kalogera, E., Scholler, N., Powless, C., et al. (2011) Correlation of Serum HE4 with Tumor Size and Myometrial Invasion in Endometrial Cancer. Gynecologic Oncology, 124, 270-275. https://doi.org/10.1016/j.ygyno.2011.10.025
|
[16]
|
Li, X., Gao, Y.P., Tan, M.Z., et al. (2015) Expression of HE4 in Endometrial Cancer and Its Clinical Significance. Biomed Research International, 2015, Article ID: 437468. https://doi.org/10.1155/2015/437468
|
[17]
|
Galgano, M.T., Hampton, G.M. and Frierson, H.F. (2006) Comprehen-sive Analysis of HE4 Expression in Normal and Malignant Human Tissues. Modern Pathology, 19, 847-853. https://doi.org/10.1038/modpathol.3800612
|
[18]
|
Quan, Q., Liao, Q.Q., Yin, W.C., et al. (2021) Serum HE4 and CA125 Combined to Predict and Monitor Recurrence of Type II Endometrial Carcinoma. Scientific Reports, 11, Article No. 21694.
https://doi.org/10.1038/s41598-021-01263-w
|
[19]
|
兰新志. 血清HE4、CA125和血浆D-二聚体在子宫内膜癌的表达及联合检测的临床价值[J]. 实验与检验医学, 2019, 37(5): 916-918.
|
[20]
|
董动丽, 顾劲松, 赵绍杰. 子宫内膜癌患者血清HE4、CA125水平变化及其意义[J]. 山东医药, 2017, 57(3): 73-75.
|
[21]
|
Luo, G.P., Jin, K.Z., Deng, S.M., et al. (2020) Roles of CA19-9 in Pancreatic Cancer: Biomarker, Predictor and Promoter. Biochimica et Biophysica Acta. Reviews on Cancer, 1875, Article ID: 188409.
https://doi.org/10.1016/j.bbcan.2020.188409
|
[22]
|
孙艳艳, 井水, 杨大平, 等. 子宫内膜癌患者血清CA125、CA199、SCC-Ag表达水平及其临床意义[J]. 医学综述, 2022, 28(3): 615-618, 624.
|
[23]
|
马丽丽. 血清CA125、CA199和骨桥蛋白联合检测在子宫内膜癌中的临床应用价值[D]: [硕士学位论文]. 新乡: 新乡医学院, 2016.
|
[24]
|
Fusetti, F., Pijning, T., Kalk, K.H., et al. (2003) Crystal Structure and Carbohydrate-Binding Properties of the Human Cartilage Glycoprotein-39. The Journal of Biological Chemistry, 278, 37753-37760.
https://doi.org/10.1074/jbc.M303137200
|
[25]
|
尹绪爱, 干宁. YKL-40在妇科恶性肿瘤中的表达和意义[J]. 国际妇产科学杂志, 2013, 40(2): 146-148, 155.
|
[26]
|
钟俊杰. CA125、CA153、CA199在卵巢癌及其转移早期诊断中作用的探讨[J]. 中外医学研究, 2013, 11(3): 51-53.
|
[27]
|
Bonneh-Barkay, D., Bissel, S.J., Kofler, J., et al. (2011) As-trocyte and Macrophage Regulation of YKL-40 Expression and Cellular Response in Neuroinflammation. Brain Pathol-ogy (Zurich, Switzerland), 22, 530-546.
https://doi.org/10.1111/j.1750-3639.2011.00550.x
|
[28]
|
魏鹏, 骆爱萍, 丁芳, 等. YKL-40表达与子宫内膜癌临床病理因素的关系[J]. 癌症进展, 2013, 11(3): 212-218.
|